Wegovy 7.2 mg: What the Higher Dose Buys

There is a higher dose now

For a long time 2.4 mg was the top of the Wegovy ladder. It is not any more. A higher dose, sold as Wegovy HD 7.2 mg, is now approved.

It exists for a specific reason: some people do not reach their goals at 2.4 mg. If that is you, this is the conversation to have. If 2.4 mg is working, there is nothing here you need.

The honest summary is that it is a trade, and both sides of it are measured.

What it buys

The trial is called STEP UP. It ran for 72 weeks across 95 clinics in 11 countries, in adults with a BMI of 30 or more and no diabetes. Nearly three-quarters of the participants were women. Mean age was 47¹.

People were split into three groups: 1,005 on semaglutide 7.2 mg, 201 on 2.4 mg, and 201 on placebo.

The difference between the two doses was 3.1 percentage points (95% CI −4.7 to −1.6)¹.

That is real, and it is worth being clear about its size. Tripling the dose buys about three extra points. For a woman weighing 90 kg, that is roughly 2.8 kg more over a year and a half.

Where the higher dose showed a bigger advantage was at the far end. Compared with 2.4 mg, people on 7.2 mg were about 1.8 times more likely to lose 20% or more, and about 2.4 times more likely to lose 25% or more¹.

So if your goal is ordinary, the extra dose adds a little. If your goal is large, it changes your odds more.

What it costs

This is the part that deserves your attention, because one side effect behaves very differently at this dose.

Look at the first row. Altered skin sensation goes from about 1 in 17 people at 2.4 mg to nearly 1 in 4 at 7.2 mg¹.

The clinical word is dysaesthesia, which tells you nothing. The label spells out what it covers: burning, tingling, skin that hurts to touch, skin that is painful when nothing is touching it, unusual sensitivity, and skin discomfort.

In plain terms: your skin may feel wrong. Sore, prickling, or burning, without anything causing it.

Do not assume that altered skin sensation is harmless. The current label reports that some affected patients needed a dose reduction, interruption or discontinuation, and some had not recovered during the trial. Persistent, painful or concerning sensory changes deserve assessment by your prescriber; do not change the dose on your own.³

The stomach effects rise too, but by much less — about ten points above 2.4 mg. If nausea is your main problem now, the higher dose will probably make it somewhat worse rather than transform it.

One number that surprised the researchers

Serious adverse events were reported by 6.8% of the 7.2 mg group and 10.9% of the 2.4 mg group¹.

Lower on the higher dose. That is the opposite of what anyone expects.

Treat it carefully rather than as good news. The 2.4 mg group had only 201 people in it against 1,005 on the higher dose, so a handful of events moves that percentage a long way. It is a reason not to assume the higher dose is dangerous. It is not evidence that it is safer.

The trial was funded by Novo Nordisk, which makes the drug, and one of the authors works there¹.

It also costs more money

The flat price does not follow you up the ladder.

Novo's own savings terms, read on 2026-08-21, price every dose from 0.25 mg to 2.4 mg at $349 a month, and Wegovy HD 7.2 mg at $399 a month².

Fifty dollars more each month, for about three extra percentage points.

How to think about it

Ask about it if you have been at 2.4 mg for a while, you have stopped moving, and you are still some distance from where you and your prescriber were aiming.

Do not ask about it if 2.4 mg is working. More dose is not more progress when the dose you are on is still doing its job.

And ask specifically about your skin. Nearly one in four is high enough that it should be part of the decision, not a surprise you discover in month three.

If the reason for considering a change is a stalled scale, the plateau guide can help you describe progress and concerns to the prescriber. If a lower-dose offer sounds like an alternative, the microdosing evidence guide explains why results from one studied regimen cannot simply be transferred to another.